Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Alogliptin/Metformin FDC vs Individual Tablets in Healthy Russian Subjects
NCT02508168Phase 1Completed
- Sponsor
- Takeda
- Start
- Apr 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of alogliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alogliptin, Maximum Observed Plasma Concentration for Alogliptin and 2 more. Started Apr 2016; status: completed.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02508168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508168.